M.D. Anderson Cancer Center
The goal of this clinical research study is to find the best dose of the drugs cyclophosphamide and axatilimab that can be given in combination with the standard dose of retifanlimab to patients with metastatic TNBC.
Primary Objective: The goal of this clinical research study is to find the best dose of the drugs cyclophosphamide and axatilimab that can be given in combination with the standard dose of retifanlimab to patients with metastatic TNBC. Secondary Objectives: The goal of this clinical research study is to find the best dose of the drugs cyclophosphamide and axatilimab that can be given in combination with the standard dose of retifanlimab to patients with metastatic TNBC.
Inclusion Criteria: * Patients must have histologically confirmed malignancy that is metastatic or locally recurrent unresectable and for which standard curative or palliative measures do not exist or are no longer effective. * Patients must have histologically or cytologically confirmed non-IBC triple negative breast cancers, defined here as ER\<1%, PR\<1% and HER2 negative per ASCO CAP 2018 guideline. OR * Inflammatory breast cancer (IBC) confirmed according to international consensus criteria that is ER\<20% and PR\<20%. * At least 1 week since prior chemotherapy or radiation therapy * Age…
Given by mouth
Given by IV
Given by IV
Arctuva estimate
Verify or correct the compensation shown for this listing.